📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
102 analysed today
FollowTelegram
102
Today
151,964
All-time analysed
43,581
Positive
6,744
Negative
92,799
Neutral
8,772
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
848 announcements match the current filters (relevance ≥ 5).
Triveni Turbine Announces ₹2.25 Interim Dividend; Record Date Set for Feb 9, 2026
Triveni Turbine Limited has declared an interim dividend of ₹2.25 per equity share (face value ₹1) for the financial year 2025-26. The company has designated February 9, 2026, as the record date for determining eligible shareholders and as the cut-off for tax document submissions. Tax will be deducted at source (TDS) at 10% for resident shareholders with a valid PAN if the dividend exceeds ₹10,000, while a 20% rate applies for those without a PAN. Non-resident shareholders may benefit from lower tax treaty rates upon submission of required documentation like Form 10F and a Tax Residency Certificate.
Key Highlights
Interim dividend of ₹2.25 per share declared for the financial year ending March 31, 2026.
Record date for dividend entitlement and tax declaration submission is Monday, February 9, 2026.
TDS of 10% applicable for resident individuals with PAN for dividend amounts exceeding ₹10,000.
Non-resident shareholders can avail lower treaty rates by submitting electronic Form 10F and TRC.
Dividend payments will be made exclusively through electronic modes as per latest SEBI mandates.
👀 What to Watch
Shareholders should ensure their PAN, bank account, and email details are updated with their Depository Participant or RTA by February 9, 2026. Eligible investors should submit Form 15G/15H or other tax exemption documents via the Alankit portal before the record date to avoid higher TDS.
Panacea Biotec's Baddi Facility Receives GMP Non-Compliance From Hungary Regulator
Panacea Biotec's subsidiary facility in Baddi has received a 'Statement of non-compliance' with Good Manufacturing Practices (GMP) from Hungary's NCPHP, resulting in the revocation of its GMP certificates. The regulator has proposed halting supplies of non-vital products to the EU market, though no quality risks were found in products already released. The financial impact is expected to be minimal as the EU market contributed only 0.32% of the company's total consolidated net revenues in FY 2024-25. The company is currently implementing corrective and preventive actions (CAPA) to seek a re-inspection and restore compliance.
Key Highlights
NCPHP Hungary issued a Statement of non-compliance with GMP for the Baddi facility on February 03, 2026.
All valid GMP certificates issued by NCPHP for the facility have been revoked following the inspection.
Revenue from the European Union market accounted for only 0.32% of consolidated net revenues in FY 2024-25.
No quality risks were observed by regulators for products already released into the market.
Company is implementing CAPA and will request a re-inspection at the earliest to restore certificates.
👀 What to Watch
Investors should note that while the immediate revenue impact is negligible at 0.32%, the regulatory failure at a major facility is a sentiment negative. Monitor the timeline for CAPA implementation and successful re-inspection to ensure no broader compliance issues exist.
SBI Card Q3 FY26: PAT Jumps 45% YoY to ₹557 Cr; Spends Hit Record ₹1.15 Lakh Cr
SBI Card reported a strong 45% YoY growth in Profit After Tax (PAT) at ₹557 crore for Q3 FY26, driven by record spends and improved credit costs. Total spends reached an all-time high of ₹1,14,702 crore, marking a 33% YoY increase, while retail spends grew by 14%. Asset quality showed significant improvement with Gross Credit Cost declining to 8.3% and Stage 2 assets reducing by ₹246 crore sequentially. Despite a slight compression in NIMs to 11%, the company maintained a healthy ROA of 3.2% and ROE of 14.7%.
Key Highlights
Profit After Tax surged 45% YoY to ₹557 crore, supported by lower credit costs and higher spend-based income.
Total spends hit a record ₹1,14,702 crore (up 33% YoY), with online spends contributing 62.1% of retail volume.
Gross Credit Cost improved to 8.3% from 9.0% in the previous quarter, reflecting better portfolio management.
Cards-in-force grew 8% YoY to 2.18 crore, maintaining an 18.8% market share in the credit card industry.
Management retained an additional provision of ₹121 crore despite an ECL-driven write-back opportunity to buffer against future volatility.
👀 What to Watch
Investors should view the improving asset quality and record spend levels as positive indicators of operational recovery. Monitor the growth in the EMI portfolio and the upcoming risk model refresh in Q4 for further margin stability.
Hester Biosciences Proposes Re-appointment of Rajiv Gandhi as CEO & MD for 3 Years
Hester Biosciences has initiated a postal ballot process to seek shareholder approval for the re-appointment of Mr. Rajiv Gandhi as CEO and Managing Director. The proposed tenure is for three years, spanning from April 1, 2026, to March 31, 2029. This move is intended to ensure leadership continuity, and the resolution is being proposed as a Special Resolution. Shareholders can participate in the remote e-voting process from February 8 to March 9, 2026.
Key Highlights
Proposed re-appointment of Mr. Rajiv Gandhi as CEO & Managing Director for a 3-year term.
The new term is scheduled to run from April 1, 2026, through March 31, 2029.
Remote e-voting period is set for February 8, 2026, to March 9, 2026, with results by March 11.
The resolution requires approval as a Special Resolution via postal ballot.
The cut-off date for shareholder eligibility was fixed as January 30, 2026.
👀 What to Watch
This is a routine leadership continuity event for the promoter-led company. Investors should support the resolution to maintain management stability, though no immediate impact on stock price is expected.
SBI Life Q3 FY26: AUM Crosses ₹5 Trillion, VNB Grows 17% to ₹50.4 Billion
SBI Life reported a strong performance for Q3 FY26, with Assets Under Management (AUM) crossing the significant ₹5 trillion milestone. The Value of New Business (VNB) grew 17% YoY to ₹50.4 billion, while VNB margins improved to 27.2% despite regulatory headwinds. Although reported Profit After Tax (PAT) grew by only 4% to ₹16.7 billion due to GST and labor law impacts, the adjusted profit growth stood at a robust 34%. The company continues to lead the private market with a 23.5% share in New Business Premium.
Key Highlights
Assets Under Management (AUM) grew 16% YoY to reach ₹5.1 trillion.
Value of New Business (VNB) increased by 17% to ₹50.4 billion with a margin of 27.2%.
Individual Rated Premium (IRP) grew 15% to ₹166.8 billion, maintaining a 25.6% private market share.
Indian Embedded Value (IEV) stood at ₹801.3 billion, representing an 18% YoY growth.
Solvency ratio remains strong at 1.91, significantly above the regulatory requirement of 1.50.
👀 What to Watch
Investors should take confidence in the company's ability to maintain margins and market leadership despite regulatory changes. The strong growth in Embedded Value and AUM suggests long-term value creation potential.
Triveni Turbine Q3 FY26: Record Revenue of ₹6.24B, 225% Interim Dividend Declared
Triveni Turbine reported its highest-ever quarterly revenue of ₹6.24 billion, a 24% YoY increase, driven by a 54% surge in export sales. While EBITDA grew 16.9% to ₹1.54 billion, PAT remained stable at ₹917 million due to a one-time ₹157 million charge related to the new wage code. The company declared an interim dividend of ₹2.25 per share and maintains a healthy order book of ₹19.86 billion. However, quarterly order bookings saw a 26% YoY decline to ₹3.91 billion, primarily due to delays in export contract closures.
Key Highlights
Highest ever quarterly Revenue of ₹6.24 billion (+24% YoY) and EBITDA of ₹1.54 billion (+16.9% YoY).
Export sales grew significantly by 54% YoY, contributing 62% to the total quarterly revenue.
Interim dividend of 225% (₹2.25 per share) approved for the financial year ending March 31, 2026.
Total outstanding order book reached a record ₹19.86 billion, up 9% YoY, providing strong future visibility.
Adjusted PAT (excluding exceptional items) grew 12.76% YoY to ₹1.04 billion.
👀 What to Watch
Investors should focus on the strong execution and record revenue, while monitoring the recovery in export order bookings which declined this quarter. The high dividend payout and robust order backlog suggest long-term stability despite short-term global trade uncertainties.
Triveni Turbine Q3 Revenue Up 32.5% YoY; Declares ₹2.25 Dividend and Re-appoints MD
Triveni Turbine reported a strong 32.5% YoY growth in standalone revenue from operations, reaching ₹5,840 million for the quarter ended December 31, 2025. The Board declared an interim dividend of ₹2.25 per share (225% of face value) with a record date of February 9, 2026. Net profit for the quarter was ₹952 million, impacted by a one-time exceptional expense of ₹157 million due to the New Labour Code. The company also ensured leadership continuity by re-appointing Mr. Nikhil Sawhney as Managing Director for a five-year term starting May 2026.
Key Highlights
Revenue from operations increased to ₹5,840 million in Q3 FY26 from ₹4,406 million in Q3 FY25.
Declared an interim dividend of ₹2.25 per equity share of face value ₹1 each.
Profit before exceptional items and tax rose 27% YoY to ₹1,452 million.
Recognized a one-time exceptional cost of ₹157 million related to employee benefit obligations under the New Labour Code.
Re-appointed Mr. Nikhil Sawhney as Vice Chairman and Managing Director for 5 years effective May 10, 2026.
👀 What to Watch
Investors should view the strong top-line growth and management continuity as positive indicators of business health. The stock remains attractive for those seeking a mix of growth in the power equipment sector and consistent dividend yields.
Triveni Turbine Q3 Revenue Up 32.5% YoY; Declares ₹2.25 Dividend and Re-appoints MD
Triveni Turbine Limited reported a robust 32.5% YoY increase in revenue from operations, reaching ₹5,840 million for the quarter ended December 31, 2025. The company declared an interim dividend of ₹2.25 per share (225% of face value) with a record date of February 9, 2026. While Profit After Tax was ₹952 million, it was impacted by a one-time exceptional charge of ₹157 million due to the New Labour Code. The board also ensured leadership continuity by re-appointing Mr. Nikhil Sawhney as Managing Director for a five-year term starting May 2026.
Key Highlights
Revenue from operations increased to ₹5,840 million in Q3 FY26 from ₹4,406 million in Q3 FY25
Declared an interim dividend of ₹2.25 per equity share with a record date of February 9, 2026
Profit before exceptional items and tax rose to ₹1,452 million compared to ₹1,140 million YoY
Re-appointment of Mr. Nikhil Sawhney as Managing Director for 5 years effective May 10, 2026
One-time exceptional expense of ₹157 million recognized for compliance with the New Labour Code
👀 What to Watch
Investors should focus on the strong 32.5% top-line growth and the healthy dividend payout as signs of operational strength. The re-appointment of the Managing Director ensures leadership stability for the next five years.
Triveni Turbine Declares ₹2.25 Interim Dividend; Q3 Revenue Up 32.5% YoY
Triveni Turbine has declared an interim dividend of ₹2.25 per share (225% of face value) for FY 2025-26, with the record date set for February 9, 2026. The company reported a strong standalone revenue growth of 32.5% YoY, reaching ₹5,840 million for the quarter ended December 31, 2025. Profit after tax stood at ₹952 million, which includes a one-time exceptional expense of ₹157 million due to the New Labour Code transition. Additionally, the board has approved the re-appointment of Nikhil Sawhney as Managing Director for a further five-year term starting May 2026.
Key Highlights
Interim dividend of ₹2.25 per equity share (225% of face value) declared.
Standalone revenue from operations grew 32.5% YoY to ₹5,840 million in Q3 FY26.
Exceptional one-time expense of ₹157 million recognized for New Labour Code compliance.
Nikhil Sawhney re-appointed as Vice Chairman and Managing Director for 5 years effective May 10, 2026.
Record date for dividend entitlement fixed as February 9, 2026, with payment by February 23.
👀 What to Watch
Investors should ensure they hold shares before the February 9 record date to qualify for the ₹2.25 dividend. The robust revenue growth and management continuity are positive indicators for long-term performance.
Triveni Turbine Declares ₹2.25 Interim Dividend; Q3 Revenue Up 32.5% YoY
Triveni Turbine Limited has declared an interim dividend of ₹2.25 per equity share for FY 2025-26, fixing February 9, 2026, as the record date. The company reported a strong standalone revenue growth of 32.5% year-on-year, reaching ₹5,840 million for the quarter ended December 31, 2025. Profitability was slightly tempered by a one-time exceptional charge of ₹157 million related to the New Labour Code transition. Additionally, the board has approved the re-appointment of Mr. Nikhil Sawhney as Managing Director for a further five-year term starting May 2026.
Key Highlights
Declared interim dividend of ₹2.25 per share (225% of face value) with payment by February 23, 2026.
Standalone revenue from operations increased to ₹5,840 million in Q3 FY26 from ₹4,406 million in Q3 FY25.
Profit before exceptional items and tax rose to ₹1,452 million, up from ₹1,140 million in the corresponding quarter last year.
Recognized a one-time exceptional expense of ₹157 million due to employee benefit obligations under the New Labour Code.
Board approved the re-appointment of Nikhil Sawhney as Vice Chairman and MD for 5 years effective May 10, 2026.
👀 What to Watch
Investors should ensure they hold shares by the February 9 record date to qualify for the dividend and may view the strong revenue growth as a sign of healthy demand in the power equipment sector.
Triveni Turbine Q3 Revenue Up 32.5% YoY to ₹5.84B; Declares ₹2.25 Interim Dividend
Triveni Turbine reported a strong 32.5% YoY increase in revenue from operations to ₹5,840 million for Q3 FY26. While reported Profit After Tax (PAT) decreased to ₹952 million from ₹1,213 million YoY, this was primarily due to a one-time exceptional charge of ₹157 million related to the New Labour Code and a high base effect from a ₹360 million gain in the previous year. Underlying operational performance remained robust with Profit Before Exceptional Items growing 27.4% YoY. The board also declared an interim dividend of ₹2.25 per share and approved the re-appointment of Nikhil Sawhney as Managing Director for five years.
Key Highlights
Revenue from operations grew 32.5% YoY to ₹5,840 million in Q3 FY26 compared to ₹4,406 million in Q3 FY25.
Profit Before Exceptional Items and Tax rose 27.4% YoY to ₹1,452 million, indicating strong core operational efficiency.
Declared an interim dividend of ₹2.25 per equity share (225% of face value) with a record date of February 9, 2026.
Recognized a one-time exceptional expense of ₹157 million in Q3 FY26 due to employee benefit obligations under the New Labour Code.
Board approved the re-appointment of Mr. Nikhil Sawhney as Managing Director for a 5-year term effective May 10, 2026.
👀 What to Watch
Investors should look past the reported PAT decline, which was impacted by non-recurring items, and focus on the healthy 27% growth in operating profits. The combination of strong revenue growth, leadership continuity, and a steady dividend payout makes this a positive update for long-term shareholders.
Rubicon Research Approves Merger with KIA Health Tech and Appoints New Independent Director
Rubicon Research has granted in-principle approval for the merger of its wholly-owned subsidiary, KIA Health Tech Private Limited, into the parent company to achieve operational synergies. KIA Health Tech, which was established for a manufacturing facility in Aurangabad, reported a net worth of ₹815.80 Lakhs and zero revenue as of March 2025. The company also strengthened its board by appointing Dr. Pradnya Saravade, a former IPS officer and SEBI investigation head, as an Independent Director. Concurrently, Mr. Anand Agarwal, a nominee of General Atlantic, has resigned from the board.
Key Highlights
In-principle approval for merger with 100% subsidiary KIA Health Tech to drive operational synergies.
Rubicon Research reported total revenue of ₹1,09,352.40 Lakhs and net worth of ₹66,778.57 Lakhs for FY25.
Appointment of Dr. Pradnya Saravade as Independent Woman Director for a 3-year term starting February 2026.
Resignation of Non-Executive Director Mr. Anand Agarwal, nominee of General Atlantic Singapore RR Pte Ltd.
Appointment of M/s. BNP & Associates as Secretarial Auditor for a five-year term through FY 2029-30.
👀 What to Watch
The merger of the wholly-owned subsidiary is a positive step toward corporate simplification and cost efficiency without equity dilution. Investors should also note the high-profile board appointment which enhances the company's governance and regulatory oversight profile.
Rubicon Research Approves Merger with KIA Health Tech and Appoints New Independent Director
Rubicon Research has granted in-principle approval for the merger of its wholly-owned subsidiary, KIA Health Tech Private Limited, which has a net worth of ₹815.80 Lakhs, to achieve operational synergies. The company also appointed Dr. Pradnya Saravade, a former IPS officer with experience at SEBI and the CBI, as an Independent Woman Director for three years. Concurrently, Mr. Anand Agarwal, a nominee of General Atlantic, has resigned from the board. Rubicon reported a total revenue of ₹1,09,352.40 Lakhs and a net worth of ₹66,778.57 Lakhs for the period ending March 31, 2025.
Key Highlights
In-principle approval for merger with KIA Health Tech (Net worth ₹815.80 Lakhs) to streamline operations.
Appointment of Dr. Pradnya Saravade as Independent Woman Director, bringing regulatory expertise from SEBI and CBI.
Resignation of General Atlantic nominee Mr. Anand Agarwal from the Board of Directors.
Rubicon's FY25 revenue stood at ₹1,09,352.40 Lakhs with a net worth of ₹66,778.57 Lakhs.
BNP & Associates appointed as Secretarial Auditor for a five-year term through FY 2029-30.
👀 What to Watch
The merger and the addition of a director with strong regulatory background enhance corporate governance and operational focus. Investors should view these structural changes as positive for long-term stability.
Rubicon Research to Merge KIA Health Tech Subsidiary; Appoints New Independent Director
Rubicon Research has granted in-principle approval for the merger of its wholly-owned subsidiary, KIA Health Tech Private Limited, to streamline operations. KIA Health Tech has a net worth of ₹815.80 Lakhs, while Rubicon reported a total revenue of ₹1,09,352.40 Lakhs for FY25. The company also strengthened its board by appointing Dr. Pradnya Saravade, a former IPS officer with SEBI and CBI experience, as an Independent Woman Director. These changes follow the resignation of Mr. Anand Agarwal, a nominee director from General Atlantic.
Key Highlights
In-principle approval for merger with KIA Health Tech Private Limited (Net worth ₹815.80 Lakhs).
Rubicon Research reported total revenue of ₹1,09,352.40 Lakhs and net worth of ₹66,778.57 Lakhs as of March 2025.
Appointment of Dr. Pradnya Saravade as Independent Woman Director for a 3-year term starting Feb 3, 2026.
Resignation of Mr. Anand Agarwal, Nominee Director of General Atlantic, due to other commitments.
Appointment of M/s. BNP & Associates as Secretarial Auditors for a five-year term through FY 2029-30.
👀 What to Watch
The merger is a positive step toward corporate simplification and operational synergy. The addition of a director with significant regulatory and investigative experience enhances the company's governance profile.
Rubicon Research Approves Merger with Subsidiary and Appoints New Independent Director
Rubicon Research has granted in-principle approval for the merger of its wholly-owned subsidiary, KIA Health Tech Private Limited, which has a net worth of ₹815.80 Lakhs. The company also announced the appointment of Dr. Pradnya Saravade, a former IPS officer with SEBI investigation experience, as an Independent Woman Director for a three-year term. This board reshuffle includes the resignation of General Atlantic nominee Mr. Anand Agarwal. Additionally, BNP & Associates has been appointed as the Secretarial Auditor for a five-year term starting FY 2025-26 to enhance compliance oversight.
Key Highlights
In-principle approval for merger with KIA Health Tech Private Limited (Net worth: ₹815.80 Lakhs).
Rubicon Research reported total revenue of ₹1,09,352.40 Lakhs for the period ending March 31, 2025.
Appointment of Dr. Pradnya Saravade as Independent Woman Director, bringing significant regulatory and investigation experience.
Resignation of Mr. Anand Agarwal, Non-Executive Director nominated by General Atlantic, effective February 3, 2026.
Appointment of M/s. BNP & Associates as Secretarial Auditor for a term spanning FY 2025-26 to FY 2029-30.
👀 What to Watch
The merger is a positive step toward operational synergy and structural simplification, while the appointment of a former SEBI official to the board strengthens governance. Investors should view these changes as constructive for long-term stability.
Rubicon Research Approves Merger with KIA Health Tech and Board Changes
Rubicon Research has granted in-principle approval for the merger of its wholly-owned subsidiary, KIA Health Tech Private Limited, to streamline operations and achieve synergies. KIA Health Tech, which was established for a manufacturing facility, had a net worth of ₹815.80 Lakhs and zero revenue as of March 2025, while Rubicon reported a revenue of ₹1,09,352.40 Lakhs. The company also appointed Dr. Pradnya Saravade, a former IPS officer with SEBI investigation experience, as an Independent Woman Director for a three-year term. Concurrently, Mr. Anand Agarwal, a nominee of General Atlantic, has resigned from the board.
Key Highlights
In-principle approval granted for the merger of wholly-owned subsidiary KIA Health Tech Private Limited with Rubicon Research.
Rubicon Research reported FY25 revenue of ₹1,09,352.40 Lakhs and a net worth of ₹66,778.57 Lakhs.
Appointment of Dr. Pradnya Saravade, a former IPS officer and SEBI investigator, as Additional Independent Woman Director.
Resignation of Mr. Anand Agarwal, Non-Executive Director nominated by General Atlantic, effective February 3, 2026.
Appointment of M/s. BNP & Associates as Secretarial Auditor for a five-year term starting FY 2025-26.
👀 What to Watch
Investors should view the subsidiary merger as a positive step toward operational efficiency and the appointment of a director with strong regulatory background as a boost to corporate governance. Monitor the progress of the merger and the integration of the Aurangabad facility.
Rubicon Research Board Approves Merger of KIA Health Tech and New Director Appointment
Rubicon Research has granted in-principle approval for the merger of its wholly-owned subsidiary, KIA Health Tech Private Limited, to drive operational synergies. As of March 31, 2025, Rubicon reported a total revenue of ₹1,09,352.40 Lakhs and a net worth of ₹66,778.57 Lakhs. The board also appointed Dr. Pradnya Saravade, a former IPS officer with experience at SEBI and CBI, as an Independent Woman Director. Additionally, Mr. Anand Agarwal, a nominee of General Atlantic, has resigned from the board.
Key Highlights
In-principle approval for merger with KIA Health Tech (Net worth ₹815.80 Lakhs) to streamline operations.
Rubicon Research FY25 revenue stood at ₹1,09,352.40 Lakhs with a net worth of ₹66,778.57 Lakhs.
Appointment of Dr. Pradnya Saravade as Independent Woman Director for a 3-year term effective Feb 3, 2026.
Resignation of General Atlantic nominee Anand Agarwal from the board effective close of business Feb 3, 2026.
Appointment of BNP & Associates as Secretarial Auditor for a five-year term through FY 2029-30.
👀 What to Watch
The consolidation of the subsidiary should improve operational efficiency and simplify the corporate structure. Investors should view the addition of a director with a strong regulatory and governance background as a positive for corporate oversight.
Rubicon Research Q3 Net Profit Jumps 91% YoY to ₹728 Million; Revenue Up 52%
Rubicon Research reported a strong performance for the quarter ended December 31, 2025, with consolidated revenue growing 51.7% YoY to ₹4,755.29 million. Net profit surged by 91.2% YoY to ₹727.97 million, driven by robust operational growth despite a significant increase in R&D spending, which nearly doubled to ₹535.94 million. For the nine-month period, the company has already surpassed its full-year FY25 profit, reaching ₹1,699.50 million. Investors should note a post-quarter GST inspection mentioned in the auditor's report, though it has not yet impacted the financial results.
Key Highlights
Consolidated Revenue from operations rose 51.7% YoY to ₹4,755.29 million in Q3 FY26.
Net Profit after tax saw a massive jump of 91.2% YoY, reaching ₹727.97 million.
Research and Development (R&D) expenditure increased significantly to ₹535.94 million from ₹269.30 million YoY.
Basic Earnings Per Share (EPS) improved to ₹4.46 in Q3 FY26 compared to ₹2.50 in the same quarter last year.
Nine-month FY26 net profit of ₹1,699.50 million has already exceeded the full-year FY25 profit of ₹1,343.61 million.
👀 What to Watch
The company shows exceptional growth momentum and high R&D focus, making it a strong growth play in the pharma space. Investors should monitor the outcome of the GST inspection mentioned in the auditor's notes for any potential liabilities.
Rubicon Research Q3 FY26 PAT Surges 91% YoY to ₹728 Million; Revenue Up 52%
Rubicon Research reported a robust Q3 FY26 with revenue growing 51.7% YoY to ₹4,755 million, driven by strong performance in the US market where 98% of revenue is USD-denominated. Net profit (PAT) saw a significant jump of 91.2% YoY to ₹728 million, while Operating EBITDA margins remained stable at 22.7%. Although gross margins saw a slight dip to 66.5% due to increased reliance on outsourced manufacturing, the company expects the upcoming Pithampur facility to be margin-accretive. The company maintains high R&D productivity with a 93% commercialization rate for its 83 active approved products.
Key Highlights
Q3 FY26 Revenue grew 51.7% YoY to ₹4,755 million; 9M FY26 PAT up 73.2% to ₹1,700 million
USD revenue reached $53 million for the quarter, representing a 46% increase compared to Q3 FY25
Operating EBITDA margins held steady at 22.7% despite higher outsourcing costs impacting gross margins
Product concentration is improving, with the top 10 products now contributing 53% of revenue versus 59% in 9M FY25
Pithampur facility ramp-up expected in Q1 CY27 to reduce outsourcing reliance and improve gross margins
👀 What to Watch
Investors should favor the strong top-line and bottom-line growth and the company's ability to maintain EBITDA margins despite supply chain shifts. Monitor the operationalization of the Pithampur facility in mid-CY26 as a key catalyst for further margin expansion.
Birla Corp Q3 FY '26: Premium Cement Mix Hits 63% as Mukutban Plant Ramps Up
Birla Corporation Limited reported a strategic focus on trade segments and premium products during its Q3 FY '26 earnings call. Premium cement sales reached 63% of total volume, helping maintain realizations despite heavy competition in the non-trade sector. The Mukutban plant showed significant operational improvement, contributing 6.3 lakh tonnes to the quarterly volume. Management also highlighted a reduced lead distance of 328 kilometers and a consolidated clinker-to-cement ratio of 1.6.
Key Highlights
Premium cement sales increased to 63% of total volume during the quarter.
Mukutban plant achieved a volume of 6.3 lakh tonnes with a CC ratio of 0.61.
Logistics efficiency improved with the average lead distance reduced to 328 kilometers.
Management tenures for the MD & CEO and Chief Marketing Officer were extended by the Board.
Company maintained a high trade-segment focus despite non-trade volumes growing nearly 99% in Bihar.
👀 What to Watch
Investors should focus on the company's ability to sustain premium pricing and the continued margin improvement from the Mukutban plant's ramp-up. The shift toward high-margin trade sales positions the company well against industry-wide pricing pressure in the non-trade segment.
